Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-HDS chemotherapy plus rituximab with autologous stem cell transplantation in B-cell lymphoma with CNS involvement
2006-006999-38Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 2 more, sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: 2-year event-free survival. Started Jul 2007; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)lymphomamature B-cell lymphoma
Beyond the preview
Go deeper on 2006-006999-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006999-38.